Rothschild Redburn initiated coverage of MiniMed Group, Inc. with a Buy rating and a $30.00 price target. The firm cited improved product offerings and market positioning as drivers of potential growth.
The research says MiniMed is well-positioned to reverse previous market share losses with new pump formats and an improved sensor. Rothschild Redburn projects revenue compound annual growth of 10.8% from 2026 through 2029.
Formerly Medtronic’s diabetes business, MiniMed is building on its large installed base of pump users. The price target implies 55% potential upside from current levels.